Abich Financial Wealth Management’s Myriad Genetics MYGN Stock Holding History

Abich Financial Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$61.4K	Buy	+8,492	New	+$50.4K	0.02%	291

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Abich Financial Wealth Management's MYGN Position: Q3 2025 in Review

Abich Financial Wealth Management opened a new position in Myriad Genetics (MYGN) in Q3 2025: 8,492 shares worth $61.4K. The stake represents 0.02% of the portfolio and ranks #291 among its holdings.

221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

Abich Financial Wealth Management held 8,492 shares of Myriad Genetics worth $61.4K as of Q3 2025.
Myriad Genetics was a new Abich Financial Wealth Management position in Q3 2025.
Myriad Genetics made up 0.02% of Abich Financial Wealth Management's portfolio in Q3 2025, its #291 holding.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Abich Financial Wealth Management's 13F filing for Q3 2025, filed 6 Nov 2025.